De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A systemic review and meta-analysis.

被引：0
|
作者：
Goldvaser, Hadar
Yasmin, Korzets Ceder
Shepshelovich, Daniel
Yerushalmi, Rinat
Sarfaty, Michal
Ribnikar, Domen
Thavendiranathan, Paaladinesh
Amir, Eitan
机构：
[1] Beilinson Med Ctr, Davidoff Ctr, Rabin Med Ctr, Kyriat Ono, Israel
[2] Beilinson Hosp 32393 Shem, Petah Tiqwa, Israel
[3] Rabin Med Ctr, Petah Tiqwa, Israel
[4] Rabin Med Ctr, Davidoff Canc Ctr, Petah Tiqwa, Israel
[5] Davidoff Canc Ctr, Petah Tiqwa, Israel
[6] Princess Margaret Canc Ctr, Toronto, ON, Canada
[7] Toronto Gen Hosp, Res Inst, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.524
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
524
引用
收藏
页数：1
相关论文
共 50 条
  • [1] De-Escalating Treatment Strategies for Patients with Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Early-Stage Breast Cancer
    Abdel-Razeq, Hikmat
    CANCERS, 2024, 16 (20)
  • [2] Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
    Garnock-Jones, Karly P.
    Keating, Gillian M.
    Scott, Lesley J.
    BIODRUGS, 2010, 24 (03) : 207 - 209
  • [3] Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)- Positive Early Breast Cancer
    Karly P. Garnock-Jones
    Gillian M. Keating
    Lesley J. Scott
    BioDrugs, 2010, 24 : 207 - 209
  • [4] Trastuzumab A Review of its Use as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
    Garnock-Jones, Karly P.
    Keating, Gillian M.
    Scott, Lesley J.
    DRUGS, 2010, 70 (02) : 215 - 239
  • [5] Erratum to: Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer
    KP Garnock-Jones
    GM Keating
    LJ Scott
    Drugs, 2011, 71 : 1578 - 1578
  • [6] Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis
    Goldvaser, Hadar
    Korzets, Yasmin
    Shepshelovich, Daniel
    Yerushalmi, Rinat
    Sarfaty, Michal
    Ribnikar, Domen
    Thavendiranathan, Paaladinesh
    Amir, Eitan
    JNCI CANCER SPECTRUM, 2019, 3 (02)
  • [7] De-escalating and escalating treatment in patients with HER2 positive breast cancer
    Joensuu, H.
    BREAST, 2017, 32 : S20 - S21
  • [8] Escalating and de-escalating treatments in HR+HER2- early-stage breast cancer
    Ge, Rui
    TRANSLATIONAL BREAST CANCER RESEARCH, 2022, 3
  • [9] Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2(HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients
    Jihong Guo
    Qing Li
    Pin Zhang
    Peng Yuan
    Jiayu Wang
    Fei Ma
    Ying Fan
    Ruigang Cai
    Yang Luo
    Qiao Li
    Binghe Xu
    ChineseJournalofCancerResearch, 2019, 31 (05) : 759 - 770
  • [10] Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients
    Guo, Jihong
    Li, Qing
    Zhang, Pin
    Yuan, Peng
    Wang, Jiayu
    Ma, Fei
    Fan, Ying
    Cai, Ruigang
    Luo, Yang
    Li, Qiao
    Xu, Binghe
    CHINESE JOURNAL OF CANCER RESEARCH, 2019, 31 (05) : 759 - 770
12345